Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

ALEXION PHARMACEUTICALS, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 1992-01-01

Employees: 3.8K

Market Cap: -

Website: http://www.alexion.com

Clinical Trials

ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly

Phase 2

Not yet recruiting

Conditions: Acromegaly

Interventions: Drug: ALXN2420
Drug: Placebo

First Posted Date: 2025-06-25

Last Posted Date: 2025-06-25

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 60

Registration Number: NCT07037420

Study of Ravulizumab in Pediatric Participants With Primary IgAN

Phase 3

Not yet recruiting

Conditions: IgAN
IgAVN
Immunoglobulin A Nephropathy
Immunoglobulin A Vasculitis Associated Nephritis
Henoch-schonlein Purpura Nephritis
IgA Vasculitis

Interventions: Drug: Ravulizumab

First Posted Date: 2025-06-17

Last Posted Date: 2025-06-22

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 18

Registration Number: NCT07024563

Locations: 🇨🇳
Research Site, Taoyuan City, Taiwan

Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

Not yet recruiting

Conditions: Generalized Myasthenia Gravis
Anti-AChR Antibody Positive

Interventions: Drug: Ravulizumab

First Posted Date: 2025-05-13

Last Posted Date: 2025-05-13

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 40

Registration Number: NCT06967480

Locations: 🇮🇹
Clinical Trial Site, Torino, Italy

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

Phase 3

Recruiting

Conditions: Delayed Graft Function
DGF
Kidney Transplant

Interventions: Drug: Ravulizumab
Drug: Placebo

First Posted Date: 2025-02-17

Last Posted Date: 2025-07-01

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 450

Registration Number: NCT06830798

Locations: 🇬🇧
Research Site, Woodville South, United Kingdom

Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG

Phase 3

Active, not recruiting

Conditions: Generalized Myasthenia Gravis (gMG)
Refractory gMG

Interventions: Drug: Eculizumab

First Posted Date: 2025-01-08

Last Posted Date: 2025-06-25

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 15

Registration Number: NCT06764160

Locations: 🇨🇳
Research Site, Wuhan, China

Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation

Phase 2

Active, not recruiting

Conditions: Antibody-Mediated Rejection
Kidney Transplantation
Biopsy-proven Histologic Scores
AMR

Interventions: Drug: ALXN2030
Drug: Placebo

First Posted Date: 2024-12-20

Last Posted Date: 2025-06-22

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 45

Registration Number: NCT06744647

Locations: 🇬🇧
Research Site, London, United Kingdom

Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD

Phase 3

Recruiting

Conditions: NMOSD
Neuromyelitis Optica Spectrum Disorders

Interventions: Drug: eculizumab

First Posted Date: 2024-12-09

Last Posted Date: 2025-05-28

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 21

Registration Number: NCT06724809

Locations: 🇨🇳
Research Site, Wuhan, China
🇨🇳
Research Site, Zhengzhou, China

PK Study of Gefurulimab SC in Healthy Chinese Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: gefurulimab

First Posted Date: 2024-11-06

Last Posted Date: 2025-05-01

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 8

Registration Number: NCT06677138

Locations: 🇨🇳
Research Site, Shanghai, China

PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

Phase 3

Recruiting

Conditions: Generalized Myasthenia Gravis
gMG

Interventions: Combination Product: Gefurulimab

First Posted Date: 2024-09-23

Last Posted Date: 2025-05-16

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 12

Registration Number: NCT06607627

Locations: 🇨🇳
Research Site, Taipei, Taiwan

Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Phase 3

Active, not recruiting

Conditions: Paroxysmal Nocturnal Hemoglobinuria
PNH

Interventions: Drug: Ravulizumab

First Posted Date: 2024-08-30

Last Posted Date: 2025-03-06

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 18

Registration Number: NCT06578949

Locations: 🇨🇳
Research Site, Wuhan, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy